IP
CLVS

Intellectus Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Intellectus Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,300
Closed -$38K – 562
2018
Q3 		$38K Buy
1,300
+250
+24% +$9.68K 0.01% 371
2018
Q2 		$48K Hold
1,050
– – 0.02% 347
2018
Q1 		$55K Hold
1,050
– – 0.02% 331
2017
Q4 		$71K Buy
1,050
+700
+200% +$48.9K 0.03% 306
2017
Q3 		$29K Hold
350
– – 0.01% 482
2017
Q2 		$33K Buy
+350
New +$21.4K 0.01% 439

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Intellectus Partners's CLVS Position: Q4 2018 in Review

Intellectus Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 1,300 shares — an estimated $38K sold.

Intellectus Partners first reported a position in CLVS in Q2 2017 and held it in 6 quarters. The position peaked at $71K in Q4 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Intellectus Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 1,300 Clovis Oncology, Inc. shares in Q4 2018, an estimated $38K.
  • Intellectus Partners first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 6 quarters.
  • Intellectus Partners's Clovis Oncology, Inc. position peaked at $71K in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.